Sareum is a specialist drug development company delivering targeted small molecule therapeutics to improve the treatment of cancer and autoimmune diseases. The Company aims to generate value through licensing its candidates to international pharmaceutical and biotechnology companies at the preclinical or early clinical trials stage.
Sareum is advancing internal programmes focused on distinct dual tyrosine kinase 2 (TYK2) / Janus kinase 1 (JAK1) inhibitors through preclinical development as therapies for autoimmune diseases, including the ‘cytokine storm’ immune system overreaction to Covid-19 and other viral infections, (SDC-1801) and cancer immunotherapy (SDC-1802).
Sareum is based in Cambridge, UK and listed on the AIM market of the London Stock Exchange, trading under the ticker SAR.
Scendea was founded as a result of a management buyout of the product development and regulatory consulting function of a clinical research organisation. Our origin dates back over 20 years, with involvement in over 1,000 development programmes.
Scendea’s expert team delivers strategic and operational support in the fields of quality/CMC, non-clinical/toxicology, clinical/medical and regulatory to successfully guide products from early development to marketing approval.
A combination of scientific excellence, industry experience, commercial awareness and a collaborative approach allow our expert team to solve complex issues associated with medicinal product development. Scendea has team members based in the UK, Ireland, the Netherlands and the US, who deliver innovative and high-quality solutions aligned to jurisdiction-specific regulatory requirements.
At Scendea we collaborate, innovate, and together with our clients, we succeed.
Science Entrepreneur Club
The Science Entrepreneur Club (SEC) is a London based non-profit organisation of curious minds that aims to explore and unite the life science ecosystem by educating, inspiring and connecting. We give scientists, innovators and startups, with a focus on biotech, pharma, medtech, bioengineering, biosustainability or related, a network and a unique platform to showcase their innovative technologies, find investors, meet like-minded people and accelerate their company.
Sekisui Diagnostics, a global provider of innovative medical diagnostics to physicians and laboratories, has been committed to improving the lives of patients for over 30 years. We continue to invest in new diagnostic products in the areas of diabetes, infectious disease, coagulation, diagnostic enzymes and automated systems. We are a leading provider of rapid tests in the U.S., and high throughput coagulation systems in Japan. We develop, manufacture, and supply over 1.7 billion tests each year to the global healthcare market through direct sales, our commercial distribution networks and our partners.
Silence Therapeutics develops a new generation of medicines by harnessing the body’s natural mechanism of RNA interference, or RNAi, within its cells.
Our proprietary technology can selectively inhibit any gene in the genome, specifically silencing the production of disease-causing proteins. Using our enabling delivery systems, we have achieved an additional level of specificity by delivering our therapeutic RNA molecules exclusively to target cells. Silence’s proprietary RNA chemistries and delivery systems are designed to improve the stability of our molecules and enhance effective delivery to target cells, providing a powerful modular technology well suited to tackle life-threatening diseases.
Sphere Fluidics is developing picodroplets and single cell analysis systems and services for therapeutic discovery.
Biopharmaceutical, lab-on-a-chip, cells, antibodies, microfluidics, enzymes, cancer, biologics, biotechnology, pharmaceutical, life sciences, immunology, oncology, cell therapies, and stem cells
Sygnature Discovery is a leading independent integrated drug discovery and pre-clinical services CRO. Founded in 2004 and private equity-backed since 2017, we operate a fully-enabled research facility in Nottingham, UK, housing nearly 400 staff (80% of our scientists have PhDs). Our experienced R&D scientists possess all the professional skills and know-how required to undertake the most demanding of drug discovery and/or pre-clinical development projects and drive them from target validation, through hit identification, hit-to-lead and lead optimization to development candidate. Sygnature collaborates with its partners via risk share and FTE-based collaborations.